Company intelligence / Profile preview

Nuotai Biotech

Nantong, Jiangsu, China

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Nuotai Biotech is a leading producer of peptide APIs, with global sales of semaglutide, liraglutide, teduglutide, and oseltamivir phosphate. The company has obtained US FDA DMF approvals for several peptides, indicating strong regulatory compliance and commercial viability. Its revenues and profits are rapidly rising due to booming GLP-1 demand, supported by expanded high-capacity manufacturing.

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyCardiovascular
Modalities: PeptidesSmall molecule
Industry: Contract Manufacturing Organization

Partnerships

Julphar (Middle East/Africa commercial partner)KrkaCiplaApotexChemoTevaDr. Reddy

Beyond the preview

Go deeper on Nuotai Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuotai Biotech.

Explore the full profile